COMMUNIQUÉS West-GlobeNewswire

MediciNova Announces MN-001 (tipelukast) NASH/NAFLD Phase 2 Trial Interim Results Selected for Presentation at the International Liver Congress 2018 in Paris, France

29/01/2018 - 00:00

LA JOLLA, Calif., Jan. 28, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV ) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875 [...]

VBI Vaccines Announces Changes to its Board of Directors

26/01/2018 - 22:15

Sam Chawla, of Perceptive Advisors, to resign from VBI Board of Directors Tomer Kariv, Chairman and CEO of The Pontifax Group, to replace Ran Nussbaum on VBI’s Board of Directors CAMBRIDGE, Mass., Jan. 26, 2018 (GLOBE [...]

TiGenix:Transparency notifications pursuant to Article 14 of the Law of May 2, 2007

26/01/2018 - 22:01

REGULATED INFORMATION PRESS RELEASE Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - January 26, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix [...]

Repros Announces Negative Opinion From the EMA for Enclomiphene

26/01/2018 - 22:01

THE WOODLANDS, Texas, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® , (Nasdaq: RPRX ) ("Repros" or the "Company") today announced that, consistent with the previously disclosed guidance from the European [...]

IntelGenx Mourns the Passing of long term Director Ian Troup

26/01/2018 - 22:00

SAINT-LAURENT, Quebec, Jan. 26, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (“IntelGenx”), (TSXV:IGX) (OTCQX:IGXT) -- The Board of Directors of IntelGenx was advised today of the passing of its long term [...]

Aviragen Comments on ISS Report

26/01/2018 - 21:59

Vaxart Merger is the Result of an Extensive Review of Strategic Alternatives and is in the Best Interest of ALL Stockholders Aviragen Board of Directors Unanimously Recommends that Stockholders Vote FOR the Proposed [...]

Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

26/01/2018 - 19:03

Lutathera marks first FDA Approval for a Peptide Receptor Radionuclide Therapy (PRRT) Advanced Accelerator Applications is a newly established subsidiary of Novartis Lutathera expands Novartis' neuroendocrine tumor [...]

Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

26/01/2018 - 18:00

First-in-class Therapy Demonstrated 79% Improvement in Progression Free Survival in NETTER-1 Phase 3 Study in Midgut NET Patients LUTATHERA ® marks first FDA Approval for a Peptide Receptor Radionuclide Therapy (PRRT) [...]

Insmed Announces Closing of Public Offering

26/01/2018 - 18:00

BRIDGEWATER, N.J., Jan. 26, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq: INSM ) announced the closing today of its previously announced public offering of its 1.75% convertible senior notes due 2025. Insmed [...]

Skyline Medical Opens New European Headquarters to Drive International Sales of the STREAMWAY System

26/01/2018 - 17:30

MINNEAPOLIS, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Skyline Medical Inc (NASDAQ: SKLN ) (“Skyline” or the “Company”), today announced that it has opened new European headquarters in Belgium and appointed Jean-Paul Rasschaert [...]

American Health Council Honors Gerald Morley, MD as “Best in Medicine”

26/01/2018 - 16:38

NEW YORK, Jan. 26, 2018 (GLOBE NEWSWIRE) -- The American Health Council honors Gerald Morley, MD as one of America’s “Best in Medicine.” With over 53 years of knowledge and expertise in Clinical Neurophysiology, Dr. [...]

Stemline Therapeutics Closes $59.6 Million Public Offering of Common Stock

26/01/2018 - 16:21

NEW YORK, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML ), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced the closing of a previously [...]

BioStem Technologies, Inc. Announces the Engagement of Investment Banking Firm Young America Capital for 15 Million Dollar 506(c) Offering.

26/01/2018 - 15:45

Pompano Beach, FL, Jan. 26, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) (“BSEM” or “Company”) announced today the engagement of investment banking firm Young America Capital as an advisor for [...]

Aquinox to Host Analyst and Investor Event in New York City

26/01/2018 - 15:05

VANCOUVER, British Columbia, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ: AQXP ), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to [...]

Medtronic Launches IDE Study to Evaluate the Abre(TM) Venous Self-Expanding Stent System in Patients with Deep Venous Disease

26/01/2018 - 15:01

Study to Enroll Subjects at up to 35 Sites Across the U.S. and Europe DUBLIN - January 26, 2018 - Medtronic plc (NYSE: MDT) today announced the initiation of its investigational device exemption (IDE) study for the Abre [...]

Arch Biopartners Announces Non Brokered Private Placement Financing

26/01/2018 - 14:50

TORONTO, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX-V: ARCH ) (OTCBB: ACHFF ) a portfolio based biotechnology company, intends to complete a non-brokered private placement [...]

Teligent, Inc. Announces the Appointment of Damian Finio as Chief Financial Officer

26/01/2018 - 14:40

BUENA, N.J., Jan. 26, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT ), a New Jersey-based specialty generic pharmaceutical company, announced today that Damian Finio has been appointed Chief Financial Officer of [...]

Hemispherx Announces Presentation on the Potential Role of Ampligen as an Immune System Amplifier Improving Seasonal Flu Vaccine Cross-Protection

26/01/2018 - 14:30

ORLANDO, Fla., Jan. 26, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announces that William Mitchell, MD, PhD, Professor of Pathology, Microbiology & [...]

FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares

26/01/2018 - 14:01

FIT Biotech Oy Company release January 26, 2018 at 03:00 PM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on December 22, 2017 [...]